Immunotherapy startups look to engineer macrophages to fight solid tumors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy
Cancer Cell International Open Access 24 November 2023
-
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Molecular Cancer Open Access 30 January 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Cancer-eating immune cells kitted out with CARs. Nat Biotechnol 38, 509–511 (2020). https://doi.org/10.1038/s41587-020-0520-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0520-5
This article is cited by
-
Biosensors based on potent miniprotein binder for sensitive testing of SARS-CoV‑2 variants of concern
Microchimica Acta (2024)
-
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Molecular Cancer (2023)
-
Holothurian triterpene glycoside cucumarioside A2-2 induces macrophages activation and polarization in cancer immunotherapy
Cancer Cell International (2023)
-
AAV-mediated delivery of a Sleeping Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells
Nature Biomedical Engineering (2023)
-
Long-term culture-expanded alveolar macrophages restore their full epigenetic identity after transfer in vivo
Nature Immunology (2022)